Transchem Ltd Stock Price Today (NSE: TRANSCHEM)
Fundamental Score
Transchem Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Transchem Ltd share price today is ₹311.20, up +2.88% on NSE/BSE as of 7 August 2026. Transchem Ltd (TRANSCHEM) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹425.77 (Cr). The 52-week high for TRANSCHEM share price is ₹370.25 and the 52-week low is ₹38.31. At a P/E ratio of 99.02x, TRANSCHEM is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 5.28% and a debt-to-equity ratio of 0.00.
Transchem Ltd Share Price Chart — NSE/BSE Historical Performance
Transchem Ltd share price chart: -10.33% return over the past month. 52-week high ₹370.25, 52-week low ₹38.31.
Transchem Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹305.00 | ₹306.00 | ₹303.00 | ₹305.00 | 6.79K (Cr) | |
| ₹300.20 | ₹315.00 | ₹300.20 | ₹304.85 | 2.84K (Cr) | |
| ₹313.00 | ₹317.00 | ₹300.00 | ₹312.55 | 4.36K (Cr) | |
| ₹290.05 | ₹314.00 | ₹285.65 | ₹302.85 | 13.06K (Cr) | |
| ₹285.05 | ₹314.55 | ₹284.65 | ₹300.65 | 44.71K (Cr) | |
| ₹328.75 | ₹328.75 | ₹312.35 | ₹315.35 | 3.36K (Cr) | |
| ₹326.55 | ₹354.50 | ₹326.55 | ₹328.75 | 7.32K (Cr) | |
| ₹337.60 | ₹358.00 | ₹337.60 | ₹343.00 | 10.66K (Cr) | |
| ₹370.25 | ₹370.25 | ₹370.25 | ₹370.25 | 5.48K (Cr) | |
| ₹362.00 | ₹363.00 | ₹362.00 | ₹363.00 | 7.73K (Cr) |
Transchem Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹290.05 | ₹317.00 | ₹285.65 | ₹305.00 | +5.15% | |
| ₹335.30 | ₹370.25 | ₹284.65 | ₹300.65 | -10.33% | |
| ₹235.25 | ₹356.15 | ₹234.65 | ₹342.10 | +45.42% | |
| ₹165.00 | ₹224.05 | ₹158.30 | ₹224.05 | +35.79% | |
| ₹165.00 | ₹189.65 | ₹141.85 | ₹165.00 | +0.00% | |
| ₹181.00 | ₹181.00 | ₹148.90 | ₹162.65 | -10.14% | |
| ₹165.00 | ₹184.65 | ₹130.05 | ₹184.65 | +11.91% | |
| ₹186.75 | ₹194.25 | ₹152.20 | ₹170.00 | -8.97% | |
| ₹100.48 | ₹183.11 | ₹100.48 | ₹183.11 | +82.24% | |
| ₹68.00 | ₹95.70 | ₹63.01 | ₹95.70 | +40.74% | |
| ₹61.01 | ₹74.02 | ₹57.95 | ₹67.42 | +10.51% | |
| ₹50.40 | ₹75.89 | ₹46.01 | ₹61.00 | +21.03% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Transchem Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Transchem Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of TRANSCHEM across key market metrics for learning purposes.
Positive Indicators
4 factors identified
Robust Profit Growth (186.30%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Balanced Promoter Holding (56.45%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
6 factors identified
Below-Average Return on Equity (5.28%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (6.89%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 99.02x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Revenue Contraction (-100.00%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Limited Institutional Interest (FII+DII: 0.04%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Transchem Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Transchem Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Transchem LtdTranschem Ltd...Selected✓ TRANSCHEM • 500422 | 35.7/100 | ₹311.20₹311 | ₹425.77₹425.77 | 99.02Average 99.0 Average | 5.28%Poor 5.28% Poor | 6.89%Poor 6.89% Poor | 0.00Excellent 0.0 Excellent | 13.93%Good 13.93% Good | — — | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Transchem Ltd PE Ratio History
Historical price-to-earnings ratio for TRANSCHEM — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹4.27 | ₹183.11 | 42.9x |
| FY 2024 | ₹3.43 | ₹51.48 | 15x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Transchem Ltd Quarterly Performance
Latest quarterly metrics for TRANSCHEM — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-100.00%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
186.30%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
13.93%
Compounded annual net profit growth over 5 years
Transchem Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for TRANSCHEM — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Transchem Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Transchem Ltd (TRANSCHEM) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Transchem Ltd
About TRANSCHEM (Transchem Ltd)
Transchem Ltd is a dynamic, research-driven pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies. We are focused on address...ing unmet medical needs in key therapeutic areas such as oncology, immunology, and central nervous system disorders. Our state-of-the-art research facilities and collaborative partnerships with leading academic institutions and biotech firms enable us to push the boundaries of pharmaceutical science. We pride ourselves on a commitment to scientific excellence, ethical practices, and patient-centricity, striving to improve the lives of individuals worldwide through the power of transformative medicines. Transchem's pipeline encompasses a diverse portfolio of novel drug candidates, from early-stage preclinical assets to late-stage clinical programs. At Transchem, we are driven by a passionate team of scientists, clinicians, and business professionals with a shared vision of creating breakthrough pharmaceuticals. Our core values are rooted in integrity, innovation, and collaboration, fostering a culture where creativity thrives and every individual is empowered to make a meaningful contribution. We maintain a strong focus on precision medicine, leveraging advanced technologies like genomics and bioinformatics to tailor treatments to individual patient profiles. This approach allows us to maximize therapeutic efficacy and minimize adverse effects. Furthermore, we are committed to sustainable and responsible practices throughout our operations, minimizing our environmental impact and supporting the communities we serve. TRANSCHEM actively seeks strategic alliances and licensing opportunities to expand our product portfolio and accelerate the delivery of novel therapies to patients. Our experienced business development team is dedicated to identifying and evaluating promising drug candidates and technologies that align with our strategic priorities. We are committed to building long-term, mutually beneficial partnerships with other pharmaceutical companies, biotech firms, and academic institutions. By combining our expertise and resources, we can collectively address the most pressing healthcare challenges and improve patient outcomes globally. TRANSCHEM is poised to emerge as a leader in the pharmaceutical industry, driven by our unwavering commitment to innovation, patient care, and global health.
Company Details
Key Leadership
Latest News
TRANSCHEM Share Price: Frequently Asked Questions
What is the current share price of Transchem Ltd?
Transchem Ltd (TRANSCHEM) trades at ₹311.20 on NSE and BSE. Market cap ₹425.77 (Cr). Educational data only.
What is the P/E ratio of Transchem Ltd?
Transchem Ltd has a P/E of 99.02x vs industry average 34.89x.
What is the Bull Run score for Transchem Ltd?
Transchem Ltd has a Bull Run score of 35.7/100 based on 25+ financial parameters.
Does Transchem Ltd pay dividends?
Transchem Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Transchem Ltd?
Transchem Ltd has ROE of 5.28%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Transchem Ltd?
Transchem Ltd has debt-to-equity of 0.00.
Is Transchem Ltd a good investment?
Bull Run gives Transchem Ltd a score of 35.7/100. This is not investment advice — consult a SEBI-registered advisor.